IMS25 Brings Together Global Thought Leaders in Riyadh The IMS25 summit marks a groundbreaking event in Riyadh, uniting over 3,000 leaders from 76 countries, showcasing major announcements poised to shape the MICE industry.

IMS25 Brings Together Global Thought Leaders in Riyadh #Saudi_Arabia #Riyadh #MICE_Industry #IMS25

IMS25 Gathering in Riyadh Marks a Historic Shift in the MICE Industry The International MICE Summit 2025 brings together over 3,000 global leaders in Riyadh, marking significant investment deals and shaping the industry's future.

IMS25 Gathering in Riyadh Marks a Historic Shift in the MICE Industry #Saudi_Arabia #Riyadh #Riyadh_Summit #MICE_Industry #IMS25

At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma | OncLive Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma #IMS25 #mmsm #hematology
www.onclive.com/view/at-3-ye...

At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma.

Click here to watch:

🎥 buff.ly/Ut0Ne7p

#MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky

🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities:

👉 buff.ly/MjL0Oku 👈

#CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25

In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma.

Click to watch:

👉 buff.ly/RVZjPoG 👈

#CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky

It was fantastic to catch up with the lovely Meral Beksac at #IMS25 to hear about strategies for improving CAR T-cell responsiveness and overcoming resistance in patients with #MultipleMyeloma.

Watch the interview here:

🎥 buff.ly/Rm44VmO

#MMsm #Myeloma #CARTCell #ImmunoOnc #BloodSky #HemeSky

In an interview from #IMS25, Doris Hansen of @moffittnews.bsky.social outlined the results from a CIBMTR study assessing the safety and efficacy of cilta-cel in R/R #MultipleMyeloma.💉🩸

Watch here:

👉 buff.ly/fMxLmKd 👈

#IMS25 #MMsm #Myeloma #ImmunoOnc #CARTCell @myeloma-society.bsky.social

To learn about the role of the immune system as a mechanism of resistance to T-cell engagers in #MultipleMyeloma, make sure to watch our recent interview from #IMS25 with Samir Parekh. 🎥🩸

Click here:

👉 buff.ly/VceerXt 👈

#MMsm #Myeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky

In an interview from #IMS25, Charlotte Pawlyn of @icr.ac.uk outlines ongoing UK-based clinical trials in #MultipleMyeloma, namely the FiTNESS and iFit trials.

Click here to learn more:

👉 buff.ly/3qAkNKA

#MMSM #HemOnc #CTSM #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma | OncLive Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma @myeloma-society.bsky.social #IMS25 #IMS2025 #mmsm #oncology www.onclive.com/view/teclist...

Watch our interview from #IMS25 with Larry Anderson to hear about the updated safety and efficacy data from the randomized Phase III AURIGA study.🩸

Click here:

🎥 buff.ly/TclKlrd

#CTSM #TrialUpdate #MMsm #Myeloma #HemOnc #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

In an interview from #IMS25, Bruno Paiva shares insights into MRD dynamics and early immunotherapy interception in #MultipleMyeloma.🩸

Watch here:

👉 buff.ly/pzzJrRm 👈

#mmMRD #MMsm #Myeloma #HemOnc #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

#IMS25 | Meera Mohan of @medicalcollegeofwi.bsky.social discusses a study investigating outcomes after a limited duration of bispecific antibody therapy in patients with R/R #MultipleMyeloma:

🎥 buff.ly/I3wa6uz

#MMsm #Myeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky @myeloma-society.bsky.social

Thank you to Claudio Cerchione for stopping by at #IMS25 to share insight into the use of anti-CD38–based quadruplet regimens for patients with transplant-ineligible #MultipleMyeloma.🩸

Check out the interview here:

👉 buff.ly/jVocJUD 👈

#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

Thank you to the lovely Hang Quach of @unimelb.bsky.social for speaking with us at #IMS25 to share results from part one of the Phase I/II DREAMM-20 trial investigating belantamab in pts with R/R #MultipleMyeloma.🩸

Watch now:

🎥 buff.ly/zBD1MpN

#MMsm #Myeloma #CTSM #TrialUpdate #ImmunoOnc #HemOnc

It's always a pleasure to catch up with Hermann Einsele!😊

At #IMS25, Prof. Einsele outlined ongoing trials in #CARTCell therapy for #MultipleMyeloma.💉🩸

Click here to watch the interview:

👉 buff.ly/Bc1gG2R 👈

#CTSM #ImmunoOnc #MMsm #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

At #IMS25, we spoke with Gareth Morgan, who provided practical advice to support earlier recognition and diagnosis of #amyloidosis.🩸

Click here to watch:

👉 buff.ly/iPaNSjm 👈

@myeloma-society.bsky.social #HemOnc #BloodSky #HemeSky #MedSky

At #IMS25, we caught up with Xavier Leleu of to hear about the Phase III IRAKLIA trial investigating isatuximab administered subcutaneously via an on-body injector versus intravenously in patients with R/R #MultipleMyeloma:

🎥 buff.ly/T67u8VR

#MMsm #Myeloma #TrialUpdate @myeloma-society.bsky.social

Findings from the phase 2 ISASOCUT study support the use of subcutaneous isatuximab plus VRd as a new standard of care in newly diagnosed MM, said Dr Arthur Bobin of @chu-poitiers.bsky.social, who presented these results at #IMS25. #IMS2025 #mmsm shorturl.at/iSblj

Want to hear the evidence supporting the use of MRD-guided treatment in #MultipleMyeloma? 🤔🩸

Check out our interview from #IMS25 with Noemi Puig:

🎥 buff.ly/CtaSWCC

#MMsm #Myeloma #mmMRD #HemOnc @myeloma-society.bsky.social

Dr Rahul Banerjee’s Top 6 Presentations From IMS 2025 Dr Rahul Banerjee shares his favorite presentations from IMS 2025 and explains why he finds them interesting.

Dr Rahul Banerjee (@rahulbanerjeemd.bsky.social) of @fredhutch.org shares his favorite presentations from #IMS25. shorturl.at/xaGmE #IMS2025 #mmsm

Isa-VRd Displays High VGPR or Better Rate in Transplant-Ineligible Newly Diagnosed Multiple Myeloma | OncLive Isa-VRd produced a VGPR or better rate of 87.8% in transplant-ineligible newly diagnosed multiple myeloma.

Isa-VRd Displays High VGPR or Better Rate in Transplant-Ineligible Newly Diagnosed Multiple Myeloma @myeloma-society.bsky.social
#IMS25 #mmsm #hematology
www.onclive.com/view/isa-vrd...

Paola Neri presents data from her recent Blood Cancer Discovery paper, "Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapies" at #IMS25.

Read the article: buff.ly/vlQra5A

Don't forget, you can still access #IMS25 meeting content. If you registered for either in-person or virtual this year, log in to the virtual platform to review all recorded sessions.

Thank you to everyone who joined #IMS25, both in person and virtually. Save the date for next year's conference, taking place September 23-26 in Glasgow, Scotland. We look forward to seeing you in 2026!

Day 4 highlights from the 22nd Annual IMS Meeting! #IMS25

Three myeloma experts made engaging & persuasive arguments for the supremacy of ADCs, bispecifics, and CAR-Ts for treating MM. No clear winner in this dynamic debate but having these options counts as a win for the race to cure myeloma! #IMS25

BKd Produces Robust Responses in Relapsed/Refractory Multiple Myeloma | OncLive Belantamab mafodotin plus carfilzomib and dexamethasone was active in patients with relapsed/refractory multiple myeloma.

BKd Produces Robust Responses in Relapsed/Refractory @myeloma-society.bsky.social #IMS25 #mmsm #hematology www.onclive.com/view/bkd-pro...

Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma | OncLive Belantamab mafodotin monotherapy was active and safe in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma @myeloma-society.bsky.social #IMS25 #mmsm www.onclive.com/view/belanta...